Croma-Pharma reports 27% revenue growth in 2022 and targets further revenue growth in 2023 and thereafter

• Company reports strong financial results for 2022 with 27% revenue growth in 2022 and
  significantly increased margins
• Growth driven by launch of Letybo^® and its catalytic effect on the existing portfolio as
  well as strong market growth
• Continued market share gains, strategic mid-term revenue growth at a CAGR of 30%
  and further improvement of operating margins targeted

Downloads